2.7(top 20%)
2-year impact
3.0(top 20%)
3-year impact
3.0(top 20%)
5-year impact
2.5(top 20%)
10-year impact
769(top 20%)
PR articles
16.9K(top 20%)
PR citations
59(top 10%)
PR h-index
63(top 10%)
h-index
2.8(top 20%)
extended IF
2.7(top 20%)
2-YI (article-only)
3.2(top 100%)
2-YI (review-only)
1.0(top 100%)
2-YI (comm only)
2.7(top 20%)
2-YI (no self-cite.)
907
documents
20.5K
doc citations

Top Articles

#TitleJournalYearCitations
1Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequencesDiabetes and Vascular Disease Research2015284
2SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trialsDiabetes and Vascular Disease Research2015281
3Metformin therapy and clinical usesDiabetes and Vascular Disease Research2008223
4Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndromeDiabetes and Vascular Disease Research2005221
5Homocysteine and cardiovascular disease: a review of the evidenceDiabetes and Vascular Disease Research2007195
6Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literatureDiabetes and Vascular Disease Research2021194
7The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patientsDiabetes and Vascular Disease Research2008191
8The endothelium and vascular inflammation in diabetesDiabetes and Vascular Disease Research2007186
9Metabolic syndrome, or What you will: definitions and epidemiologyDiabetes and Vascular Disease Research2007185
10Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shiftDiabetes and Vascular Disease Research2019181
11Review article: Coagulation and fibrinolysis in diabetesDiabetes and Vascular Disease Research2010171
12Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetesDiabetes and Vascular Disease Research2006164
13Cellular and molecular mechanisms of endothelial dysfunction in diabetesDiabetes and Vascular Disease Research2013160
14Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetesDiabetes and Vascular Disease Research2019158
15Review article: Platelet abnormalities in diabetes mellitusDiabetes and Vascular Disease Research2010154
16Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA ® )Diabetes and Vascular Disease Research2015153
17The impact of smoking on the development of diabetes and its complicationsDiabetes and Vascular Disease Research2017153
18ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – SummaryDiabetes and Vascular Disease Research2014146
19New perspectives on the management of diabetic peripheral neuropathic painDiabetes and Vascular Disease Research2006132
20Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) studyDiabetes and Vascular Disease Research2006131
21Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiologyDiabetes and Vascular Disease Research2013124
22The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE −/− mouse modelDiabetes and Vascular Disease Research2013123
23Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitusDiabetes and Vascular Disease Research2016121
24The insulin resistance syndrome: physiological considerationsDiabetes and Vascular Disease Research2007116
25Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseasesDiabetes and Vascular Disease Research2018113
26Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesisDiabetes and Vascular Disease Research2018107
27Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritisDiabetes and Vascular Disease Research2007106
28Gaps and barriers in the control of blood glucose in people with type 2 diabetesDiabetes and Vascular Disease Research2017104
29Impaired glucose tolerance and impaired fasting glucose — a review of diagnosis, clinical implications and managementDiabetes and Vascular Disease Research2005103
30Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluationDiabetes and Vascular Disease Research2012103
31Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney diseaseDiabetes and Vascular Disease Research2012102
32The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysisDiabetes and Vascular Disease Research2018100
33Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trialDiabetes and Vascular Disease Research201399
34Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitorDiabetes and Vascular Disease Research201596
35The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolismDiabetes and Vascular Disease Research200895
36All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individualsDiabetes and Vascular Disease Research200594
37Review article: Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitusDiabetes and Vascular Disease Research201093
38Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failureDiabetes and Vascular Disease Research200483
39Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitusDiabetes and Vascular Disease Research200783
40Platelet hyperactivity in type 2 diabetes: role of antiplatelet agentsDiabetes and Vascular Disease Research200883
41Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-κB pathwayDiabetes and Vascular Disease Research201479
42Thrifty genes for obesity and the metabolic syndrome — time to call off the search?Diabetes and Vascular Disease Research200678
43GLP-1 receptor agonists: A clinical perspective on cardiovascular effectsDiabetes and Vascular Disease Research201276
44Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosisDiabetes and Vascular Disease Research201775
45Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitusDiabetes and Vascular Disease Research200768
46Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease statusDiabetes and Vascular Disease Research201368
47Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetesDiabetes and Vascular Disease Research201568
48Mammalian hibernation: a naturally reversible model for insulin resistance in man?Diabetes and Vascular Disease Research200867
49Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: A nationwide observational study from the Swedish National Diabetes RegisterDiabetes and Vascular Disease Research201366
50Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practiceDiabetes and Vascular Disease Research201866